Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies (ADVM) Prices 9.5M Share Common Offering at $13.75/Sh

February 12, 2020 5:50 AM EST

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced the pricing of its underwritten public offering of 9,500,000 shares of its common stock at a public offering price of $13.75 per share. The company has granted the underwriters a 30-day option to purchase up to an additional... More

UPDATE: Cantor Fitzgerald Upgrades Adverum Biotechnologies (ADVM) to Overweight

February 9, 2020 4:46 PM EST

(Updated - February 10, 2020 6:34 AM EST)

(updated to add analyst comments)

Cantor Fitzgerald analyst Alethia Young upgraded Adverum Biotechnologies (NASDAQ: ADVM) to Overweight with a price target of $21 (from $8).

The analyst commented, "We attended Angiogenesis this weekend where Adverum... More